FIRST CONFIRMED SARS-COV-2 DELTA VARIANT IN SERBIA

Valentina D Opancina; Jorge Juan  Lara Bohoyo; Christina  Alcazar Perez; Ana Todorovic; Miljan Opancina; Ruzica  Radojevic Marjanovic; Radisa Vojinovic

doi:10.5937/mckg55-33862

Valentina D Opancina Fakultet medicinskih nauka, Univerzitet u Kragujevcu
Jorge Juan Lara Bohoyo
Christina Alcazar Perez University of Murcia, Spain, Faculty of Medicine
Ana Todorovic University of Kragujevac, Serbia, Faculty of Medical Sciences
Miljan Opancina University of defense, Military Medical Academy, Medical Faculty, Belgrade, Serbia
Ruzica Radojevic Marjanovic University Clinical Center “Kragujevac”, Kragujevac, Serbia
Radisa Vojinovic University of Kragujevac, Serbia, Faculty of Medical Sciences, Department of Radiology

DOI: https://doi.org/10.5937/mckg55-33862

Keywords: COVID-19; SARS-CoV-2; Delta variant.

Abstract

Severe acute respiratory syndrome coronavirus 2 is a Betacoronavirus of 2B group that belongs to the family of Coronaviridae. Delta variant, which emerged in the Indian State of Maharashtra in December 2020, is nowadays the variant of concern most widespread and it consists on 3 subtypes, B.1.617.1, B.1.617.2, B.1.617.3. The transmission rate of Delta variant is 50%-60% higher than the Alpha variant and this variant is what currently concerns the world population.

In this paper, we present the case of a firste registered patient with Delta variant of COVID-19 in Serbia.

Author Biography

Jorge Juan Lara Bohoyo

University of Malaga, Spain, Faculty of Medicine

References

1. Lazarevic I, Pravica V, Miljanovic D, Cupic M. Immune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far? Viruses 2021; 13(7):1192. doi: 10.3390/v13071192.
2. Adil MT, Rahman R, Whitelaw D, et al. SARS-CoV-2 and the pandemic of COVID-19. Postgrad Med J 2021; 97(1144):110-116. doi: 10.1136/postgradmedj-2020-138386.
3. Salian VS, Wright JA, Vedell PT, et al. COVID-19 Transmission, Current Treatment, and Future Therapeutic Strategies. Mol Pharm 2021; 18(3): 754-771. doi: 10.1021/acs.molpharmaceut.0c00608.
4. Edara VV, Pinsky BA, Suthar MS, et al. Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants. N Engl J Med 2021; 385(7): 664-666. doi: 10.1056/NEJMc2107799.
5. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). 2021 Jul 30. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021. PMID: 32150360.
6. Campbell F, Archer B, Laurenson-Schafer H, et al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. Euro Surveill 2021; 26(24): 2100509. doi: 10.2807/1560-7917.ES.2021.26.24.2100509.
7. Singh J, Rahman SA, Ehtesham NZ, Hira S, Hasnain SE. SARS-CoV-2 variants of concern are emerging in India. Nat Med 2021; 27(7):1131-1133. doi: 10.1038/s41591-021-01397-4.
8. Rosenberg ES, Holtgrave DR, Dorabawila V, et al. New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status - New York, May 3-July 25, 2021. MMWR Morb Mortal Wkly Rep 2021; 70(34):1150-1155. doi: 10.15585/mmwr.mm7034e1.
9. Rao V, Arakeri G, Madikeri G, Shah A, S Oeppen R, A Brennan P. Post-COVID Mucormycosis in India: A formidable challenge. Br J Oral Maxillofac Surg 2021;doi:10.1016/j.bjoms.2021.06.013
10. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med 2021; 385(7): 585-594. doi: 10.1056/NEJMoa2108891.